Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effects of different hemodialysis modalities combined with low-calcium dialysate on mineral metabolism and vascular calcification in maintenance hemodialysis patients with chronic kidney disease

J. Wang, Y. Luo, X. Ji, H. Xu, Z. Liang, M. Zhou

. 2024 ; 22 (4) : 228-233. [pub] 20241216

Language English Country Czech Republic

Document type Journal Article, Randomized Controlled Trial

Grant support
2022A029 President Foundation of Nanfang Hospital, Southern Medical University - China

OBJECTIVE: This research investigated the effects of different hemodialysis modalities combined with low-calcium dialysate (LCD) on mineral metabolism and vascular calcification (VC) in maintenance hemodialysis (MHD) patients with chronic kidney disease (CKD). METHODS: General data were collected from 192 cases of MHD patients, who were divided into 4 groups according to the randomized numerical table. Each group was given LCD treatment, and conventional hemodialysis (HD), high-flux HD (HFHD), hemodiafiltration (HDF), and HD + hemoperfusion (HP) were performed, respectively. The patients were dialyzed 3 times per week for 4 h each time, and each group was treated for 6 months. Fasting venous blood was collected. Serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and high-sensitive C-reactive protein (hs-CRP) levels were measured by ELISA, calcium (Ca2+), phosphorus (P), Ca2+-P product, serum creatinine (SCr), blood urea nitrogen (BUN), β2 microglobulin (β2-MG), and intact parathyroid hormone (iPTH) were measured by chemiluminescence immunoassay, serum alkaline phosphatase (ALP) was determined by turbidimetric assay, and 25-hydroxyvitamin D (25(OH)D) was measured by autoradiographic immunoassay. To assess the extent of calcification in the iliac artery and abdominal aorta, a multilayer spiral CT device was employed for abdominal scans. RESULTS: Serum IL-6, hs-CRP, TNF-α, Ca2+, P, Ca2+-P product, SCr, BUN, β2-MG, iPTH, and ALP levels decreased, while 25(OH)D levels increased in the four groups after treatment. The most pronounced effect on the reduction of IL-6, hs-CRP, TNF-α, Ca2+, P, Ca2+-P product, SCr, BUN, β2-MG, iPTH, and ALP was in the HD + HP group, followed by the HDF and HFHD groups, and then by the HD group. The rate of VC in the HDF, HFHD, and HD + HP groups was lower than that in the HD group, and the rate in the HD + HP group was lower than that in the HDF and HFHD groups. CONCLUSION: The combination of HD + HP and LCD in treating CKD with MHD is effective, evidently rectifying disruptions in serum Ca2+ and P metabolism, enhancing kidney function, lessening the body's inflammatory response, and lessening VC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25011851
003      
CZ-PrNML
005      
20250521143007.0
007      
ta
008      
250506s2024 xr f 000 0|eng||
009      
AR
024    7_
$a 10.32725/jab.2024.027 $2 doi
035    __
$a (PubMed)40033811
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Wang, Jing $u Southern Medical University, Nanfang Hospital, Blood Purification Unit, Guangzhou 510515, Guangdong China
245    10
$a Effects of different hemodialysis modalities combined with low-calcium dialysate on mineral metabolism and vascular calcification in maintenance hemodialysis patients with chronic kidney disease / $c J. Wang, Y. Luo, X. Ji, H. Xu, Z. Liang, M. Zhou
520    9_
$a OBJECTIVE: This research investigated the effects of different hemodialysis modalities combined with low-calcium dialysate (LCD) on mineral metabolism and vascular calcification (VC) in maintenance hemodialysis (MHD) patients with chronic kidney disease (CKD). METHODS: General data were collected from 192 cases of MHD patients, who were divided into 4 groups according to the randomized numerical table. Each group was given LCD treatment, and conventional hemodialysis (HD), high-flux HD (HFHD), hemodiafiltration (HDF), and HD + hemoperfusion (HP) were performed, respectively. The patients were dialyzed 3 times per week for 4 h each time, and each group was treated for 6 months. Fasting venous blood was collected. Serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and high-sensitive C-reactive protein (hs-CRP) levels were measured by ELISA, calcium (Ca2+), phosphorus (P), Ca2+-P product, serum creatinine (SCr), blood urea nitrogen (BUN), β2 microglobulin (β2-MG), and intact parathyroid hormone (iPTH) were measured by chemiluminescence immunoassay, serum alkaline phosphatase (ALP) was determined by turbidimetric assay, and 25-hydroxyvitamin D (25(OH)D) was measured by autoradiographic immunoassay. To assess the extent of calcification in the iliac artery and abdominal aorta, a multilayer spiral CT device was employed for abdominal scans. RESULTS: Serum IL-6, hs-CRP, TNF-α, Ca2+, P, Ca2+-P product, SCr, BUN, β2-MG, iPTH, and ALP levels decreased, while 25(OH)D levels increased in the four groups after treatment. The most pronounced effect on the reduction of IL-6, hs-CRP, TNF-α, Ca2+, P, Ca2+-P product, SCr, BUN, β2-MG, iPTH, and ALP was in the HD + HP group, followed by the HDF and HFHD groups, and then by the HD group. The rate of VC in the HDF, HFHD, and HD + HP groups was lower than that in the HD group, and the rate in the HD + HP group was lower than that in the HDF and HFHD groups. CONCLUSION: The combination of HD + HP and LCD in treating CKD with MHD is effective, evidently rectifying disruptions in serum Ca2+ and P metabolism, enhancing kidney function, lessening the body's inflammatory response, and lessening VC.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a dialýza ledvin $x škodlivé účinky $7 D006435
650    _2
$a mužské pohlaví $7 D008297
650    12
$a vápník $x krev $x metabolismus $7 D002118
650    _2
$a lidé středního věku $7 D008875
650    12
$a vaskulární kalcifikace $x krev $7 D061205
650    12
$a chronická renální insuficience $x terapie $x krev $x komplikace $x metabolismus $7 D051436
650    _2
$a senioři $7 D000368
650    _2
$a minerály $x metabolismus $x krev $7 D008903
650    _2
$a TNF-alfa $x krev $7 D014409
650    _2
$a interleukin-6 $x krev $7 D015850
650    _2
$a dialyzační roztoky $x farmakologie $7 D015314
650    _2
$a fosfor $x krev $7 D010758
650    _2
$a parathormon $x krev $7 D010281
650    _2
$a dospělí $7 D000328
650    _2
$a C-reaktivní protein $x metabolismus $x analýza $7 D002097
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Luo, Yimian $u Southern Medical University, Guangzhou 510515, Guangdong, China
700    1_
$a Ji, Xingyu $u Southern Medical University, Guangzhou 510515, Guangdong, China
700    1_
$a Xu, Hao $u Southern Medical University, Guangzhou 510515, Guangdong, China
700    1_
$a Liang, Zhenhua $u Southern Medical University, Guangzhou 510515, Guangdong, China
700    1_
$a Zhou, Minjie $u Southern Medical University, Nanfang Hospital, Department of Organ Transplantation, Guangzhou 510515, Guangdong, China
773    0_
$w MED00012667 $t Journal of applied biomedicine $x 1214-0287 $g Roč. 22, č. 4 (2024), s. 228-233
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40033811 $y Pubmed
910    __
$a ABA008 $b B 2301 $c 1249 $y p $z 0
990    __
$a 20250506 $b ABA008
991    __
$a 20250521143005 $b ABA008
999    __
$a ok $b bmc $g 2324879 $s 1248941
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 22 $c 4 $d 228-233 $e 20241216 $i 1214-0287 $m Journal of applied biomedicine $n J Appl Biomed $x MED00012667
GRA    __
$a 2022A029 $p President Foundation of Nanfang Hospital, Southern Medical University $2 China
LZP    __
$b NLK124 $a Pubmed-20250506

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...